Federal Western District Courthouse in Lafayette

Federal Court Affirms Louisiana’s Case on Abortion Pills—But Stops Short of Needed Action

From Louisiana Right to Life Staff

On April 7, 2026, the U.S. District Court for the Western District of Louisiana (Lafayette Division) issued a significant ruling in the State of Louisiana’s challenge to the FDA’s deregulation of the abortion drug mifepristone. While the decision marks meaningful progress, it ultimately falls short of the action warranted by the court’s own findings.

A Clear Recognition of Harm—and Legal Merit

In its decision, the court affirmed that Louisiana has standing to bring this case—recognizing both the sovereign harm to the state and the real financial burden placed on Louisiana taxpayers through Medicaid costs tied to abortion pill complications.

This is a critical development. In contrast to previous cases dismissed on technical grounds, the court made clear that Louisiana is directly affected by the FDA’s actions and has every right to challenge them.

Even more notably, the court found that Louisiana is likely to succeed on the merits of its claims. The judge pointed to serious concerns with how the FDA removed key safety protections in 2023, including:

• The elimination of in-person medical oversight
• The expansion of mail-order abortion pills
• The agency’s reliance on incomplete or insufficient safety data

In short, the court acknowledged that the FDA likely failed to follow the law in implementing these changes.

The Missing Step: No Injunction

Despite these findings, the court declined to issue an injunction that would have restored basic safety safeguards—such as requiring in-person dispensing of abortion drugs.

Instead, the court chose to pause the case while the FDA conducts its own internal review.

This is where the ruling falls short.

If the court recognizes that:

• Louisiana is being harmed, and
• The FDA likely acted unlawfully

then the logical and appropriate step would have been to grant immediate relief to prevent further harm.

Allowing the current policy to remain in place—while acknowledging its likely legal deficiencies—leaves women exposed to continued risk and allows the consequences to persist.

Where the Case Goes Next

The case is now temporarily stayed while the FDA reviews its own actions. However, this is not the end of the road.

Louisiana remains in a strong legal position. The court’s findings lay important groundwork for future action, and the state retains the ability to return to court if the FDA fails to correct its course.

Given the strength of the court’s findings, an appeal to the U.S. Court of Appeals for the Fifth Circuit to seek the injunction that was denied at the district level could be an option. The Fifth Circuit has previously recognized serious flaws in the FDA’s handling of abortion pill regulations, and it may be better positioned to provide the immediate relief that this situation demands.

Moving Forward

We are encouraged by the momentum of this case and the court’s clear acknowledgment of both the harm to Louisiana and the legal shortcomings of the FDA’s actions.

But recognition alone is not enough.

When a policy is likely unlawful and causing ongoing harm, it should not remain in place.

Louisiana has taken an important step forward—but the fight for accountability, and for real protections for women, must continue.

Louisiana Right to Life is especially grateful for the leadership of Attorney General Liz Murrill in advancing this case and defending the state’s pro-life laws. We also recognize the courage of Rosalie Markezich, whose willingness to come forward underscores the real-world impact of these policies and the importance of seeking justice.